ArticleSurgery2026
Transarterial therapies versus portal vein embolization prior to major hepatectomy: A national comparison of perioperative outcomes.
Article in Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPreoperative liver remnant hypertrophy has historically been achieved with portal vein embolization, but transarterial embolizations, such as radioembolization, have gained interest as alternative hypertrophy mechanisms in select patients. National practice patterns and outcomes between these 2 modalities are poorly characterized. The objective of this study is to compare preoperative utilization of transarterial therapies versus portal vein embolization and assess perioperative outcomes.
methodsThe American College of Surgeons National Surgical Quality Improvement Program database was queried for patients undergoing right hepatectomy or trisegmentectomy after preoperative portal vein embolization or transarterial embolization between 2014 and 2024. Univariable and multivariable regression analyses were performed to identify factors associated with utilization, perioperative transfusion, posthepatectomy liver failure, and serious morbidity.
resultsAmong 1,240 patients who met inclusion criteria, 1,068 (86.1%) underwent portal vein embolization and 172 (13.9%) underwent transarterial embolization. Transarterial embolization utilization increased from 8.8% in 2014 to 23.7% in 2024 (P < .001). In multivariable analysis, patients were more likely to receive transarterial embolization if they underwent resection in 2020 and after (odds ratio, 2.17; 95% confidence interval, 1.46-3.26; P < .001) or had hepatocellular carcinoma (odds ratio, 4.35; 95% confidence interval, 2.41-7.99; P < .001). Rates of transfusion (374/1,068 [35.0%] vs 61/172 [35.5%], P = .978), serious posthepatectomy liver failure (120/1,068 [11.2%] vs 17/172 [9.9%], P = .695), and serious morbidity (391/1,068 [36.6%] vs 59/172 [34.3%], P = .618) were comparable between portal vein embolization and transarterial embolization, respectively, with no further differences on adjusted multivariable analysis.
conclusionUtilization of transarterial embolization prior to major hepatectomy has increased over the past decade with no associated increase in relative morbidity. In appropriate clinical scenarios, transarterial embolization may serve as a reasonable alternative to portal vein embolization prior to major hepatectomy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.